Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
- Author:
Masayuki SARUTA
1
;
Dong Il PARK
;
Young-Ho KIM
;
Suk-Kyun YANG
;
Byung-Ik JANG
;
Jae Hee CHEON
;
Jong Pil IM
;
Takanori KANAI
;
Tatsuro KATSUNO
;
Yoh ISHIGURO
;
Makoto NAGAOKA
;
Naoki ISOGAWA
;
Yinhua LI
;
Anindita BANERJEE
;
Alaa AHMAD
;
Mina HASSAN-ZAHRAEE
;
Robert CLARE
;
Kenneth J. GORELICK
;
Fabio CATALDI
;
Mamoru WATANABE
;
Toshifumi HIBI
Author Information
- Publication Type:Original Article
- From:Intestinal Research 2020;18(1):45-55
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background/Aims:PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7+ lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD).
Methods:OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients.
Results:In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7+ central memory CD4+ T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment.
Conclusions:In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509)
